Novelix Pharmaceuticals share price & results

NOVELIX PHARMACEUTICALS LIMITED

Results to: Sept 2022
Ownership as of: Jul 2026

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

Metric	Value	Change	Basis	Period	Note
Revenue	1.2 ₹ crore	−49.6% YoY	Quarterly, as filed	Quarter to Sept 2022	Revenue from operations as filed.
Operating margin	-15.3 %	−21.4 pts YoY	Operating profit / revenue	Quarter to Sept 2022	For the quarter; a change is in percentage points.
Net profit	-0.15 ₹ crore	−142.9% YoY	Quarterly, as filed	Quarter to Sept 2022	Profit after tax as filed.
Return on equity	Unavailable	+14.6 ptsFY Mar 2022 vs FY Mar 2021	Trailing twelve months	TTM · period unavailable	Not in the analysed materials. No older figure is substituted.
Free cash flow margin	Unavailable	−18.6 ptsFY Mar 2022 vs FY Mar 2021	Fiscal year	FY · period unavailable	Not in the analysed materials. No older figure is substituted.
Revenue growth (YoY)	Unavailable	+4.5 ptsFY Mar 2022 vs FY Mar 2021	Trailing twelve months	TTM · period unavailable	Not in the analysed materials. No older figure is substituted.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Sept 2022

Price

₹60.03 +1.40% · +₹0.83

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +26.5% 1Y

1Y: ₹47.45 on 24 Oct 2025 → ₹60.03. High ₹88.8 (16 Jun 2026), low ₹47.45 (24 Oct 2025).

Previous close: ₹59.2
Market cap: ₹112 Cr
52-week range: ₹49.81 – ₹88.8
One year: +20.52%

Overview

Symbol: NSE:NOVELIX
Exchange: NSE
Currency: INR

Fundamentals

Ratios, each with its period

Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2017 to Mar 2022).

Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
— — — — — —

How it is calculated. Market capitalisation from the current stock record.

Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
—	—	—	—	—	—

A dash means inputs are missing or too old, the ratio does not apply, or the value is outside the supported range. FY uses the reported fiscal period; TTM the latest twelve months; valuations use the current market cap with the chosen earnings period. Screen Indian stocks on these ratios →

Financials

What the filings say

Net profit, year on year: −143% (quarter to sept 2022 against sept 2021).

In ₹ crore. Oldest period first.

Line item	Dec 2020	Mar 2021	Jun 2021	Sept 2021	Dec 2021	Mar 2022	Jun 2022	Sept 2022
Sales	2	3	4	2	1	1	1	1
Expenses	2	6	5	2	2	2	2	1
Operating profit	-0	-3	-0	0	-1	-2	-0	-0
Operating margin	−11.4%	−130.7%	−3.9%	6.1%	−87.4%	−237.7%	−10.3%	−15.3%
Other income	0	0	0	0	0	0	0	0
Interest	0	0	0	0	0	0	0	0
Depreciation	0	0	0	0	0	-0	0	0
Profit before tax	-0	-3	-0	0	-1	-1	-0	-0
Tax rate	0.0%	0.0%	60.0%	20.9%	−22.3%	6.1%	0.0%	0.0%
Net profit	-0	-3	-0	0	-1	-2	-0	-0
EPS (₹ per share)	-0.26	-4.05	-0.19	0.40	-0.77	-1.67	-0.09	-0.16

Source: Inve data · income statement, quarterly · to Sept 2022

In ₹ crore. Oldest period first.

Line item	Mar 2021	Mar 2022
Sales	9	9
Expenses	13	11
Operating profit	-4	-3
Other income	0	1
Interest	0	0
Depreciation	0	0
Profit before tax	-4	-2
Net profit	-4	-2

Source: Inve data · income statement, annual · to Mar 2022

In ₹ crore. Oldest period first.

Line item	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Sept 2022
Equity capital	8	8	8	8	8	8
Reserves	3	3	3	-1	-1	-1
Borrowings	1	1	1	0	0	1
Other liabilities	1	1	2	3	1	0
Total liabilities	14	13	14	10	9	8
Fixed assets	2	2	2	2	2	2
Capital work in progress	0	0	0	0	0	0
Investments	1	0	0	0	0	0
Other assets	11	11	12	8	6	6
Total assets	14	13	14	10	9	8

Source: Inve data · balance sheet · to Sept 2022

In ₹ crore. Oldest period first.

Line item	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Cash from operations	-2	0	-1	1	2	2
Cash from investing	0	-1	0	0	0	-1
Cash from financing	1	0	-0	-0	-1	0
Net cash flow	-1	-0	-0	1	1	1
Free cash flow	-3	0	-0	1	2	-0

Source: Inve data · cash flow · to Mar 2022

In days and %. Oldest period first.

Line item	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Debtor days	49	75	112	44	53	50
Inventory days	48	43	38	44	48	44
Days payable	28	40	39	80	112	39
Cash conversion cycle	70	78	111	8	-11	56
Working capital days	382	322	324	285	117	88
Return on capital employed	0.9%	−0.1%	−0.8%	−0.7%	−38.2%	−25.7%
Dividend payout	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: Inve data · annual ratios · to Mar 2022

Ownership

Who owns it

Promoters hold 54.29% as of Jul 2026.

Promoters +3.72 pts 54.29%
Public −3.74 pts 45.69%

3,127 shareholders on the register.

Source: Exchange shareholding filings · to Jul 2026 · 8 filings held

Who was buying across the market this quarter

Who bought this quarter

since Jun 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

+2.06 pp 35.13% held
+1.29 pp 10.21% held
+0.86 pp 4.21% held
newly disclosed 0.35% held

The same filing shows 8 holders trimming and 2 off the list — both are in the register beside this.

Who is on the register

Named in the Jul 2026 filing

Every holder of NOVELIX PHARMACEUTICALS LIMITED above SEBI's 1% disclosure line, and what changed since Jun 2026.

Holder	Stake	Change
	35.13%	+2.06 pp
	10.21%	+1.29 pp
	6.43%	−1.23 pp
	4.21%	+0.86 pp
	3.40%	−0.65 pp
	3.05%	−0.58 pp
	2.55%	−0.48 pp
	2.20%	−0.42 pp
	2.02%	−0.38 pp
	1.40%	−0.27 pp
	0.35%	−0.07 pp
	0.35%	newly disclosed

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Your own record

Start an Inve Case for NOVELIX PHARMACEUTICALS LIMITED

Free account: one company. Everything above stays public.

Write why you follow NOVELIX PHARMACEUTICALS LIMITED and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Learn to analyse NOVELIX PHARMACEUTICALS LIMITED

Guides on how to read this kind of business and the numbers that matter.